iPrEx study

The iPrEx study tested whether a daily pill containing tenofovir and emtricitabine could prevent HIV infection in men who have sex with men and transgender women. Participants took the pill every day, and researchers compared those who took it consistently to those who didn’t. The study found that daily use reduced the risk of HIV infection by about 44%, demonstrating that pre-exposure prophylaxis (PrEP) can be an effective prevention tool when taken regularly. It highlighted the importance of adherence to medication for optimal protection and contributed to HIV prevention strategies worldwide.